Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy” consensus rating. Each stock also presents more than 40% upside potential within the next year, making them compelling investment choices.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Let’s dive into the details.
Why Low P/E Stocks?
Low P/E stocks trade at a discount to their earnings, letting you buy more profit per dollar invested. This inherent margin of safety buffers against market dips and losses. While some chase high P/E names for rapid growth, history shows low P/E picks often yield better long-term returns with lower risk. They also tend to offer generous dividends, hail from established companies with steady growth, and exhibit less volatility.
IonQ (IONQ)
- P/E Ratio: 5.5x
- Average IONQ Price Target: $65.91 (43% upside)
IonQ is a U.S.-based quantum computing company that develops trapped-ion quantum computers and is working to build a full-stack quantum ecosystem. The company is seeing strong revenue growth and rising demand, but it remains highly volatile and risky. Despite these risks, analysts remain bullish on IONQ stock due to its early-mover advantage in quantum computing and long-term growth potential. Looking ahead, the company is set to report its Q1 2026 results on May 6.
Geo Group (GEO)
- P/E Ratio: 8.9x
- Average Geo Group Price Target: $30.33 (63% upside)
The Geo Group runs private prisons, immigration detention centers, re-entry programs, and electronic monitoring services through long-term government contracts in the U.S. and internationally. It operates around 100 facilities worldwide. Investors view GEO stock as risky but potentially rewarding, supported by its low P/E valuation. The company will report its Q1 2026 results on May 12.
CorMedix (CRMD)
- P/E Ratio: 5.1x
- Average Cormedix Price Target: $13.25 (79.3% upside)
CorMedix is a biopharmaceutical company focused on developing and selling treatments for infectious and inflammatory diseases. The company will announce its Q1 2026 results on May 7. Its Pipeline advancements include Phase 3 data for REZZAYO expected in Q2 2026 and ongoing trials for DefenCath in TPN patients, targeting rising demand from aging populations and chronic diseases.